Acromegaly Update

Ethan Weiss
  • 0.0 (0)
  • Life Sciences
  • Updated weekly

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

  1. 1 day ago

    Acromegaly Update — Monday August 3, 2026

    It's a quiet week for acromegaly-specific research — no trials, just incremental papers on AI-assisted detection, surgical outcomes, and pediatric gigantism — while the broader rare disease industry saw a gene-editing "gold rush" for a liver/lung disorder, a financing bet against two bigger rivals in Angelman syndrome, and a pulmonary hypertension partnership fall apart after a near-miss trial.

  2. 27 Jul

    Acromegaly Update — Monday July 27, 2026

    A trio of new Pituitary papers built out the real-world case for oral paltusotine in controlled acromegaly, while on the industry side a small rare-disease repurposing startup inked a licensing deal and orphan drugmakers pushed back on Medicare price-pilot exposure.

  3. 20 Jul

    Acromegaly Update — Monday July 20, 2026

    A quiet week for acromegaly research was anchored by a strong AI-diagnosis paper in JCEM, while rare disease headlines swung between a startup's ultrasound gene-therapy bombshell and a somber earnings-style readout on a rare endocrine disorder.

  4. 13 Jul

    Acromegaly Update — Monday July 13, 2026

    It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pharmaceuticals, maker of the acromegaly drug Palsonify, directly linking this week's two segments.

  5. 6 Jul

    Acromegaly Update — Monday July 6, 2026

    It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on a kidney-transplant antiviral and an FDA age expansion for Vertex's CRISPR therapy Casgevy.

  6. 29 Jun

    Acromegaly Update — Monday June 29, 2026

    Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.

  7. 22 Jun

    Acromegaly Update — Monday June 22, 2026

    A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses — while the rare disease industry continues to see a wave of FDA regulatory reversals benefiting gene therapy developers.

  8. 15 Jun

    Acromegaly Update — Monday June 15, 2026

    Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.

See All (16)

About

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

Information

  • Creator
    Ethan Weiss
  • Years Active
    2026
  • Episodes
    16
  • Rating
    Clean
  • Copyright
    © Ethan Weiss / Marea Therapeutics
  • Show Website
    Acromegaly Update

You Might Also Like